Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Int J Infect Dis. 2022 Sep;122:874-884. doi: 10.1016/j.ijid.2022.07.050. Epub 2022 Jul 26.
This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated.
In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively.
The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemotherapy were risk factors for lower antibody titers. The frequencies of activated and resting MBCs decreased in (17.45% vs 38.11%, P = 0.002; 16.98% vs 34.13%, P = 0.023), while the frequencies of intermediate and atypical MBCs increased in cancer patients (40.06% vs 19.87%, P = 0.010; 25.47% vs 16.61%, P = 0.025). The serum antibody titer decreased gradually during follow-up but increased when a booster vaccine was given.
The inactivated COVID-19 vaccines were well tolerated in patients with GI cancer but with lower immunogenicity. The subpopulations of MBCs were disordered in cancer patients, and a booster vaccine may be prioritized for them.
本研究旨在评估胃肠道（GI）癌症患者使用灭活 COVID-19 疫苗的安全性和免疫原性。还研究了记忆 B 细胞（MBC）在 COVID-19 疫苗接种后体液反应中的作用。
在这项前瞻性观察研究中，纳入了接受 2 剂灭活 COVID-19 疫苗的 GI 癌症患者和健康个体。前瞻性收集不良事件、血清抗受体结合域（RBD）-IgG、中和抗体（NAb）和 MBC 频率的数据。
灭活 COVID-19 疫苗安全且耐受性良好。癌症患者的血清抗-RBG-IgG 和 NAb 较低。年龄较大、ASA 评分较高和接受积极化疗是抗体滴度较低的危险因素。活化和静止 MBC 的频率降低（17.45%比 38.11%，P=0.002；16.98%比 34.13%，P=0.023），而中间型和非典型 MBC 的频率增加（40.06%比 19.87%，P=0.010；25.47%比 16.61%，P=0.025）。在随访期间，血清抗体滴度逐渐下降，但给予加强疫苗后增加。
在 GI 癌症患者中，灭活 COVID-19 疫苗耐受性良好，但免疫原性较低。癌症患者的 MBC 亚群紊乱，可能优先考虑加强疫苗。
